FRNM
FRNM
US35661P1003
Freenome, Inc.
Loading chart...

Company Profile

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Latest News

Related stocks

BLLN
BLLN • United States
BillionToOne, Inc.
98.09 USD
4.63B USD
CSTL
CSTL • United States
Castle Biosciences, Inc.
34.42 USD
1.05B USD 1Y +42.9%
FLGT
FLGT • United States
Fulgent Genetics, Inc.
21.74 USD
598.18M USD 1Y -8.8%
OPK
OPK • United States
Opko Health, Inc.
1.38 USD
1.03B USD 1Y -11.6%
NEO
NEO • United States
NeoGenomics, Inc.
16.35 USD
2.13B USD 1Y +74.7%
WGS
WGS • United States
GeneDx Holdings Corp.
67.33 USD
2.01B USD 1Y -44.8%
RDNT
RDNT • United States
RadNet, Inc.
70.91 USD
5.58B USD 1Y -10.3%
PSNL
PSNL • United States
Personalis, Inc.
16 USD
1.71B USD 1Y +85%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
27.7% p.a.
Max Drawdown (3Y)
-29.6%
Sharpe Ratio (3Y)
0.69
Beta Factor
0.45
Size Class
Small Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
ende